Australia · Delayed Price · Currency is AUD Emyria Earnings Call Transcripts
Fiscal Year 2026
-
Clinic network expanded from one to five, driving a 475% increase in patients treated and revenue growth from AUD 1.3M to over AUD 4M. Strong clinical outcomes, new partnerships, and global momentum position the business as a leader in psychedelic-assisted therapy.
-
FY 2026 revenue surged 210% year-over-year to AUD 4.3 million, driven by clinic expansion and strong patient demand. Perth Clinic reached profitability, and regulatory changes are easing therapist recruitment. The business is well-funded, with further growth expected as new clinics open and global partnerships develop.
-
Quarterly revenue rose to AUD 1.2 million, with strong clinical outcomes and expanding clinic footprint. Regulatory catalysts and global partnerships are driving growth, while increased funding and new indications are expected to further accelerate momentum.